Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077372959> ?p ?o ?g. }
- W2077372959 endingPage "361" @default.
- W2077372959 startingPage "328" @default.
- W2077372959 abstract "Type 2 diabetes mellitus (T2DM) is a worldwide public health challenge. Despite the availability of many antidiabetes agents and pharmacotherapies targeting cardiovascular risk factors, the morbidity, mortality and economic consequences of T2DM are still a great burden to patients, society, health care systems and the economy. The need for new therapies for glycaemic control is compounded by the fact that existing treatments have limitations either because of their side effects (particularly weight gain and hypoglycaemia) or contraindications that limit their use. Furthermore, none of the current therapies have a significant impact on disease progression. Incretin-based therapies offer a new therapeutic approach to the management of T2DM, and there are also several even newer therapies in development. There are two groups of incretin-based therapies currently available; dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 analogues/mimetics. The former are given orally while the latter subcutaneously. These drugs result in glucose-dependent insulin secretion and glucose-dependent glucagon suppression, with consequent low risk of hypoglycaemia when used as mono- or combination therapy (except when used with sulphonylureas). In addition, they are either weight neutral in the case of DPP-4 inhibitors or cause weight loss in the case of incretin mimetics/analogues. Furthermore, animal studies have shown that these agents prolong beta cell survival which offers the theoretical possibility of slowing the progression to T2DM. In this article we will review the currently available antidiabetes agents with particular emphasis on incretin-based and future therapies. In addition, we will review and discuss the evidence relating to glycaemic control and cardiovascular disease." @default.
- W2077372959 created "2016-06-24" @default.
- W2077372959 creator A5023295361 @default.
- W2077372959 creator A5053833959 @default.
- W2077372959 creator A5058112799 @default.
- W2077372959 creator A5090743194 @default.
- W2077372959 date "2010-02-01" @default.
- W2077372959 modified "2023-10-09" @default.
- W2077372959 title "Glycaemic control in type 2 diabetes: Targets and new therapies" @default.
- W2077372959 cites W1507814807 @default.
- W2077372959 cites W1526927233 @default.
- W2077372959 cites W1585447752 @default.
- W2077372959 cites W172609984 @default.
- W2077372959 cites W1867945356 @default.
- W2077372959 cites W1910418518 @default.
- W2077372959 cites W1913239326 @default.
- W2077372959 cites W1933125341 @default.
- W2077372959 cites W1960382620 @default.
- W2077372959 cites W1964162607 @default.
- W2077372959 cites W1964478407 @default.
- W2077372959 cites W1964832108 @default.
- W2077372959 cites W1967130535 @default.
- W2077372959 cites W1967331905 @default.
- W2077372959 cites W1967477040 @default.
- W2077372959 cites W1969389642 @default.
- W2077372959 cites W1969415064 @default.
- W2077372959 cites W1970406523 @default.
- W2077372959 cites W1970498822 @default.
- W2077372959 cites W1970638723 @default.
- W2077372959 cites W1971471384 @default.
- W2077372959 cites W1972204120 @default.
- W2077372959 cites W1973383046 @default.
- W2077372959 cites W1973976170 @default.
- W2077372959 cites W1975588287 @default.
- W2077372959 cites W1975756049 @default.
- W2077372959 cites W1976287166 @default.
- W2077372959 cites W1976367840 @default.
- W2077372959 cites W1976503602 @default.
- W2077372959 cites W1977119153 @default.
- W2077372959 cites W1977619586 @default.
- W2077372959 cites W1978432888 @default.
- W2077372959 cites W1979982110 @default.
- W2077372959 cites W1980130009 @default.
- W2077372959 cites W1980288013 @default.
- W2077372959 cites W1980790007 @default.
- W2077372959 cites W1981183973 @default.
- W2077372959 cites W1982778753 @default.
- W2077372959 cites W1984588810 @default.
- W2077372959 cites W1984635769 @default.
- W2077372959 cites W1984740259 @default.
- W2077372959 cites W1985739127 @default.
- W2077372959 cites W1986085856 @default.
- W2077372959 cites W1988031087 @default.
- W2077372959 cites W1991565451 @default.
- W2077372959 cites W1991738016 @default.
- W2077372959 cites W1993041062 @default.
- W2077372959 cites W1993287695 @default.
- W2077372959 cites W1994636940 @default.
- W2077372959 cites W1994743271 @default.
- W2077372959 cites W1994832750 @default.
- W2077372959 cites W1995095187 @default.
- W2077372959 cites W1995265458 @default.
- W2077372959 cites W1995330160 @default.
- W2077372959 cites W1996407482 @default.
- W2077372959 cites W1998717083 @default.
- W2077372959 cites W2000047428 @default.
- W2077372959 cites W2000083483 @default.
- W2077372959 cites W2001097346 @default.
- W2077372959 cites W2001592873 @default.
- W2077372959 cites W2002937262 @default.
- W2077372959 cites W2003444892 @default.
- W2077372959 cites W2004507897 @default.
- W2077372959 cites W2004977380 @default.
- W2077372959 cites W2005693445 @default.
- W2077372959 cites W2008753682 @default.
- W2077372959 cites W2011499650 @default.
- W2077372959 cites W2012437459 @default.
- W2077372959 cites W2012506661 @default.
- W2077372959 cites W2013851956 @default.
- W2077372959 cites W2016147073 @default.
- W2077372959 cites W2017147713 @default.
- W2077372959 cites W2018192866 @default.
- W2077372959 cites W2019002829 @default.
- W2077372959 cites W2020035047 @default.
- W2077372959 cites W2020638064 @default.
- W2077372959 cites W2020787870 @default.
- W2077372959 cites W2022101780 @default.
- W2077372959 cites W2023462541 @default.
- W2077372959 cites W2024567427 @default.
- W2077372959 cites W2025578932 @default.
- W2077372959 cites W2027249582 @default.
- W2077372959 cites W2027275601 @default.
- W2077372959 cites W2028272916 @default.
- W2077372959 cites W2029084557 @default.
- W2077372959 cites W2029214914 @default.
- W2077372959 cites W2030861315 @default.
- W2077372959 cites W2031468509 @default.
- W2077372959 cites W2033198459 @default.